APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment

Conclusion: We show an in vivo effect of the GSM E2012 on the processing of APLP1 which is measurable in CSF. These data suggest that APLP1 peptides may be used as biomarkers to monitor drug effects of GSMs on γ-secretase processing in clinical trials. However, this requires further investigation in larger cohorts, including studies in man.
Source: Epidemiologic Perspectives and Innovations - Category: Epidemiology Authors: Source Type: research